TuHURA Biosciences (NASDAQ:HURA) Issues Earnings Results, Beats Expectations By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) posted its quarterly earnings results on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Stock Performance

TuHURA Biosciences stock traded up $0.01 during mid-day trading on Friday, reaching $2.05. The company’s stock had a trading volume of 162,567 shares, compared to its average volume of 279,969. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.20. The business’s 50 day simple moving average is $2.45 and its 200 day simple moving average is $2.74. The company has a market capitalization of $105.08 million and a price-to-earnings ratio of -1.18.

Analyst Ratings Changes

Several research firms have recently weighed in on HURA. Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Wednesday, October 8th. Finally, Maxim Group lowered their price target on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $10.33.

Institutional Trading of TuHURA Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $97,000. Geode Capital Management LLC lifted its stake in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the last quarter. Jane Street Group LLC acquired a new position in TuHURA Biosciences in the 1st quarter valued at approximately $69,000. Vanguard Group Inc. raised its holdings in TuHURA Biosciences by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after purchasing an additional 35,426 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in TuHURA Biosciences during the second quarter valued at $79,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.